CGEM Stock Balance Sheets

Cullinan Oncology Quarterly Balance Sheets Chart

Quarterly

Annual

Cullinan Oncology Quarterly Balance Sheets Table

Quarterly

Annual

Unit: USD	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2014-12-31	2014-09-30	2014-06-30	2013-12-31	2013-09-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-03-31	2010-12-31	2010-09-30

assets
current assets:
cash	91	470	610	36,393	118	35	2,172	2,352	2,375	2,270	875	1,376	251	3,089	1,681	576	3,911	309	1,410	3,850
receivables	3,344	3		2,544		364	1,510	3	1,233	5,422	55,951
total current assets	3,435	473	1,110	127,966	118	2,299	6,342	2,355	4,814	12,744	57,038	6,706	9,549	17,991	23,417	5,669	20,341	5,052	2,591	6,141
total assets	3,435	473	1,110	127,966	118	2,299	16,342	12,355	14,814	22,744	67,038	6,706	9,549	17,991	23,417	5,669	20,341	5,052	2,591	6,141
liabilities and stockholders’
current liabilities:
accounts payable and accrued expenses	247,877	217,225	211,135	155,574	156,742	115,977	85,432	56,933	50,510	54,658	34,575	35,685	65,104	41,852	66,962	36,516	9,480	41,760	30,849	10,463
total current liabilities	247,877	217,225	211,135	1,067,376	156,742	115,977	85,432	56,933	50,510	54,658	34,575	35,685	65,104	41,852	66,962	36,516	9,480	41,760	30,849	10,463
non-current liabilities:
advances from affiliate	330,408	285,574	272,024	382,759	1,088,175	1,088,275	1,066,199	1,027,446	1,022,696	972,838	946,915	314,125	257,136	220,467	156,837	137,093	81,804	1,541,938
total non-current liabilities	330,408	285,574	272,024	382,759	1,088,175	1,088,275	1,066,199	1,027,446	1,022,696	972,838	946,915		257,136
total liabilities	578,285	502,799	483,159	1,450,135	1,244,917	1,204,252	1,151,631	1,084,379	1,073,206	1,027,496	981,490	349,810	322,240	262,319	223,799	173,609	91,284	1,583,698	1,532,628	1,415,462
stockholders’
preferred stock: us.0001 par value, 20,000,000 shares authorised, none issued and outstanding.
common stock: us.0001 par value 500,000,000 shares authorised, and 199,873,683 and 175,315,350 issued and outstanding at december 31, 2016 and 2015	20,077
additional paid-in-capital	2,557,723				1,574,323		1,574,323			1,574,323			1,640,432						21,120
accumulated		-3,080,126	-3,059,849	-2,913,317		-2,793,101			-2,649,540								-160,470	-48,609	-1,568,437	-1,447,721
total stockholders’			-482,049	-1,322,169		-1,201,953			-1,058,392		-914,452	-343,104	-312,691	-244,328	-200,382	-167,940	-70,943	-1,578,646	-1,530,037
total liabilities and stockholders’	3,435		1,110	127,966	118	2,299	16,342	12,355	14,814	22,744	67,038	6,706	9,549	17,991	23,417	5,669	20,341	5,052	2,591
see notes to financial statements
revenues
costs and expenses
legal, accounting and professional	103,905	15,335	12,993				60,365	10,171	9,431	60,513	8,230	10,637	54,719	10,417	7,092	9,378	10,310	11,283	71,188
administration expenses	93,492						57,796			64,132
acquisition related expenses	116,946		116,946
(loss) from operations		-21,650	-145,230						-23,234		-12,124	-24,860	-175,567	-39,004	-35,155	-32,754	-48,811	-26,242	-895,774
foreign currency exchange			-1,302									-5,553	-3,714			-1,776		-22,367	-174,316
(loss) before income tax		-20,277	-146,532						-24,979		-7,966	-30,413	-179,281	-43,946	-32,442	-34,530	-43,020	-48,609	-1,070,081
benefit from income tax
net		-20,277	-146,532						-24,979		-7,966	-30,413	-179,281	-43,946	-32,442	-34,530	-43,020	-48,609	-1,070,081
basic net (loss) per common equivalent shares		0	0						0		0	0	0	0	0	0	0	0	-0.01
weighted number of common equivalent shares	192,451	199,874	194,328				175,315	175,315	175,315	175,315	175,315	175,315	175,315	175,315	175,315	175,315	175,315		172,800
non-current assets:
deposits							10,000	10,000	10,000	10,000	10,000
total non-current assets							10,000	10,000		10,000
liabilities and stockholders'
stockholders'
preferred stock: us.0001 par value, 20,000,000 share authorised none issued and outstanding
common stock: us.0001 par value 500,000,000 shares authorised, and 199,873,683 and 175,315,350 shares issued and outstanding at september 30, 2016 and december 31, 2015		20,077
additional paid-in capital		2,557,723	2,557,723	1,574,323		1,574,323		1,574,323	1,574,323		1,574,323	1,640,432		1,640,432	1,640,432	1,640,432	1,640,432	21,120		21,120
total stockholders'		-502,326
total liabilities and stockholders'		473
cost and expenses
administration expense		6,315	15,291					3,460	9,896		3,894	14,223	120,848	28,587	28,063	23,376	38,501	14,959	61,308
foreign currency exchange gain		1,373
prepayments			500	89,029		1,900	2,660		1,206	5,052	212	5,330	9,298	14,902	21,736	5,093	16,430	4,743	1,181	2,291
common stock: us.0001 par value 500,000,000 shares authorised, and 199,873,683 and 175,315,350 shares issued and outstanding at june 30, 2016 and december 31, 2015			20,077
advances from other				911,802
common stock: us.0001 par value 500,000,000 shares authorised, and 175,315,350 shares issued and outstanding				16,825		16,825		16,825	16,825		16,825
foreign currency exchange gain/									-1,745		4,158			-4,942	2,713		5,791
common stock: us.0001 par value 500,000,000 shares authorised, and 175,315,350 issued and outstanding					16,825		16,825			16,825
a
exploration expenses							10,633			574,389
95,438
interest - other										1									9
exploration expenditure									3,907
non-current assets
accumulated (deficit) during development stage											-1,505,228	-1,568,437	-1,568,437	-1,568,437	-1,568,437	-1,568,437	-1,568,437	-1,568,437
accumulated (deficit) prior to exploration stage											-410,179
retained (deficit) during exploration stage
accumulated (deficit) during exploration stage											-590,193
non current liabilities:
total non current liabilities												314,125		220,467	156,837	137,093	81,804	1,541,938	1,501,779	1,404,999
common stock: .0001 par value 500,000,000 shares authorised, and 175,315,350 shares issued and outstanding												17,532		17,532	17,532	17,532
accumulated (deficit) subsequent to development stage												-432,631	-402,218	-333,855	-289,909	-257,467
common stock: .0001 par value 500,000,000 shares authorised, and 175,315,350 issued and outstanding													17,532
other income - interest
common stock: .0001 par value 500,000,000 shares authorised, and 175,315,350 and 172,800,000 shares issued and outstanding																	17,532
common stock: .0001 par value 500,000,000 shares authorised, and 172,800,000 shares issued and outstanding																		17,280	17,280	17,280
weighted number of common equivalent
shares																		172,800
advances from axis																			1,501,779
contractors & consultants																			763,278
liabilities and stockholders’ equity
advances payable – affiliate																				1,404,999
stockholders’ equity
total stockholders’ equity																				-1,409,321
total liabilities and stockholders’ equity																				6,141

We provide you with 20 years of balance sheets for Cullinan Oncology stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Cullinan Oncology. Explore the full financial landscape of Cullinan Oncology stock with our expertly curated balance sheets.

The information provided in this report about Cullinan Oncology stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.